This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
Side effects are rare. Reported adverse events include seizures, changes in color vision, blood clots, and allergic reactions such as anaphylaxis. Whether the risk of venous thromboembolism (blood clots) is increased is a matter of debate. The risk is mentioned in the product literature, and they were reported in post marketing experience. Despite this, and the inhibitory effect of tranexamic acid on blood clot breakdown, large studies of the use of tranexamic acid have not shown an increase in the risk of venous or arterial thrombosis, even in people who had previously experienced thrombosis under other circumstances. For pregnancy, no harm has been found in animal studies. Small amounts appear in breast milk if taken during lactation. Tranexamic acid was first synthesized in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines.
The American Society for Pharmacology and Experimental Therapeutics (ASPET) is a scientific society founded in late 1908 by John Jacob Abel of Johns Hopkins University (also the founder of the American Society for Biochemistry and Molecular Biology), with the aim of promoting the growth of pharmacological research. Many society members are researchers in basic and clinical pharmacology who help develop disease-fighting medications and therapeutics. ASPET is one of the constituent societies of the Federation of American Societies for Experimental Biology (FASEB). The society's headquarters are in Rockville, MD. The current president is Michael F. Jarvis.
The predecessor of modern countercurrent chromatography theory and practice was countercurrent distribution (CCD). The theory of CCD was described in the 1930s by Randall and Longtin. Archer Martin and Richard Laurence Millington Synge developed the methodology further during the 1940s. Finally, Lyman C. Craig introduced the Craig countercurrent distribution apparatus in 1944 which made CCD practical for laboratory work. CCD was used to separate a wide variety of useful compounds for several decades.
Another use for affinity chromatography is the purification of specific proteins using a gel matrix that is unique to a specific protein. For example, the purification of E. coli β-galactosidase is accomplished by affinity chromatography using p-aminobenyl-1-thio-β-D-galactopyranosyl agarose as the affinity matrix. p-aminobenyl-1-thio-β-D-galactopyranosyl agarose is used as the affinity matrix because it contains a galactopyranosyl group, which serves as a good substrate analog for E. coli β-Galactosidase. This property allows the enzyme to bind to the stationary phase of the affinity matrix and β-Galactosidase is eluted by adding increasing concentrations of salt to the column. Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
Large aromatic residues (tyrosine, phenylalanine, tryptophan) and β-branched amino acids (threonine, valine, isoleucine) are favored to be found in β-strands in the middle of β-sheets. Different types of residues (such as proline) are likely to be found in the edge strands in β-sheets, presumably to avoid the "edge-to-edge" association between proteins that might lead to aggregation and amyloid formation. A very simple structural motif involving β-strands is the β-hairpin, in which two antiparallel strands are linked by a short loop of two to five residues, of which one is frequently a glycine or a proline, both of which can assume the dihedral-angle conformations required for a tight turn or a β-bulge loop. Individual strands can also be linked in more elaborate ways with longer loops that may contain α-helices.
Sources: en.wikipedia.org
TMEM125 has two variant transcripts that differ only in the 5' untranslated region (UTR), but both encode the same protein. mRNA variant 1 represents the longer of the two variants and is 1898 base pairs (bp) in length; variant 2 is 1797 bp long. TMEM125 microarray-assessed expression patterns in normal human tissue demonstrate the primary tissues of expression are the pancreas, lungs, salivary glands, trachea, brain, prostate, spinal cord, and thyroid. Additionally, RNA-seq data illustrates transcript expression in the following additional tissue: colon, small intestines, prostate, and stomach. TMEM125 comprises 219 amino acids with four transmembrane domains. Its predicted isoelectric point is 8.32 and predicted molecular weight is 22.1 kDa. It is primarily leucine-rich, and secondarily alanine- and glycine-rich; TMEM125 is also arginine- and lysine-deficient. It has two core repeat blocks, VALL and TTSS, which both appear twice within the protein. The secondary structure of TMEM125 is predicted to consist of α-helices and small segments of β-sheets.
The use of trapezoidal rule in AUC calculation was known in literature by no later than 1975, in J.G. Wagner's Fundamentals of Clinical Pharmacokinetics. A 1977 article compares the "classical" trapezoidal method to a number of methods that take into account the typical shape of the concentration plot, caused by first-order kinetics. Notwithstanding the above knowledge, a 1994 Diabetes Care article by Mary M. Tai entitled "A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves" purports to have independently discovered the trapezoidal rule. In Tai's response to the later letters to the editors, she explained that the rule was new to her colleagues, who relied on grid-counting. Tai's paper has been discussed as a case of scholarly peer review failure. Despite the number of mathematically superior numerical integration schemes (such as those outlined in Wagner & Ayres 1977), the trapezoidal rule remains the convention for AUC calculation. Later focus on improving the accuracy of AUC calculation shifted from improving the method to improving the sampling scheme. An example is a 2019 algorithm known as OTTER: it performs a fit onto sum of exponentials curve for the input data but only uses it to suggest better sample times by finding more highly sloped periods.
The idea of Food Social Security stemmed from noticing various flaws inherent to the current food system such as malnutrition, food insecurity, farmers' precarity and environmental concerns. Globally, while enough food is produced to feed ten billion people, food systems are threatening both human health and environmental sustainability. Food bank demand is soaring throughout the world, and is in itself not seen as a long-term response to food insecurity. Poor nutrition is generally linked to lower incomes, causing one of the largest public health challenges for children, and a significant strain on healthcare systems. The three fundamental principles of Food Social Security are:
Auto-oxidation reaction is also observed with common ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, and 1,4-dioxane. An illustrative product is diethyl ether peroxide. Such compounds can result in a serious explosion when distilled. To minimize this problem, commercial samples of THF are often inhibited with butylated hydroxytoluene (BHT). Distillation of THF to dryness is avoided because the explosive peroxides concentrate in the residue. Although ether hydroperoxide often form adventitiously (i.e. autoxidation), they can be prepared in high yield by the acid-catalyzed addition of hydrogen peroxide to vinyl ethers: C2H5OCH=CH2 + H2O2 → C2H5OCH(OOH)CH3 Many industrial peroxides are produced using hydrogen peroxide. Reactions with aldehydes and ketones yield a series of compounds depending on conditions. Specific reactions include addition of hydrogen peroxide across the C=O double bond: R2C=O + H2O2 → R2C(OH)OOH In some cases, these hydroperoxides convert to give cyclic diperoxides:
argon (E938), a inert gas used for canned products helium (E939), a inert gas used for canned products nitrogen (E941), a nonreactive packaging gas and propellant carbon dioxide (E290), a nonreactive packaging gas and propellant Specific kinds of packaging gases are aerosol propellants. These process and assist the ejection of the product from its container. chlorofluorocarbons known as CFC (E940 and E945), now rarely used because of the damage that they do to the ozone layer: dichlorodifluoromethane (E940) chloropentafluoroethane (E945) nitrous oxide (E942), used for aerosol whipped cream canisters (see Nitrous oxide: Aerosol propellant) octafluorocyclobutane (E946) These must be used with caution as they may have adverse effects when exposed to certain chemicals. They will cause oxidisation or contamination to certain types of materials. oxygen (E948), used e.g. for packaging of vegetables hydrogen (E949)
Sources: en.wikipedia.org
7. Ir Med J. 2013 May;106(5):148-9. Atypical melanocytic naevi following melanotan injection. Reid C(1), Fitzgerald T, Fabre A, Kirby B. Author information: (1)Dermatology Department, St Vincent's University Hospital, Elm Park, Dublin 4. C.Reid@st-vincents.ie Melanotan is a synthetic analogue of alpha melanocyte stimulating hormone (a-MSH) that stimulates melanogenesis. It is sold on the internet and tanning salons as a quick 'tanning jab'. We report a patient who developed multiple new onset atypical naevi within one week of receiving two Melanotan injections. This case highlights the potential risk of Melanotan in stimulating dysplastic naevi or possibly malignant melanoma.
Pyzdek, T, "Quality Engineering Handbook", 2003, ISBN 0-8247-4614-7 De Feo, J. A., "Juran's Quality Handbook", 2016, ISBN 978-1-25964-361-3 ASTM E105 Standard Practice for Probability Sampling of Materials ASTM E122 Standard Practice for Calculating Sample Size to Estimate, With a Specified Tolerable Error, the Average for Characteristic of a Lot or Process ASTM E141 Standard Practice for Acceptance of Evidence Based on the Results of Probability Sampling ASTM E1402 Standard Terminology Relating to Sampling ASTM E1994 Standard Practice for Use of Process Oriented AOQL and LTPD Sampling Plans ASTM E2234 Standard Practice for Sampling a Stream of Product by Attributes Indexedby AQL Sampling procedures for inspection by attributes, ISO 2859-1:1999 Sampling procedures for inspection by attributes, JIS Z 9015-1:2006 Acceptance Sampling Calculators (SQC Online) (A subscription fee is required to use the calculators. The "free" calculations have locked features.)
Genes for one or multiple cargo proteins with specific targeting peptides. Regulatory or accessory genes that enhance functionality or interaction with other pathways. Genes encoding the encapsulin shell protein. Encapsulins can be classified into four different families based on their cargo type and operon structure. These encapsulins likely evolved in response to the need for intracellular iron homeostasis. This family of encapsulins typically encapsulate peroxidases of ferritin-like proteins. They are characterized by the encapsulin shell proteins encoded alongside ferritin-like proteins as cargo. The operons usually include genes for ferroxidase enzymes, critical for iron oxidation. They belong to the Pfam family (Encapsulating Protein for Peroxidase) and use short C-terminal targeting (TPs) for cargo loading. This family of encapsulins provide a controlled environment for iron storage and detoxification, as well as preventing oxidative stress.
Seizures are characterized by high levels of synchronized neuronal activity. One important regulator of neuronal activity is the hyperpolarizing A-type current mediated by potassium channel KV4.2. miR-324-5p downregulates KV4.2, exacerbating conditions that lead to seizure onset, and downregulation of miR-324-5p in mouse models of epilepsy is seizure-suppressive. Changes in miRNA expression are seen in epileptogenesis and in other disease pathologies. In epilepsy, miR-324-5p expression has been shown to increase and decrease at different timepoints and loci. Importantly, miR-324-5p has increased association with the RISC complex following seizure in mice, indicating more suppressive activity. Overall, this suggests that miR-324-5p plays a role in epileptogenesis via targeting of potassium channel KV4.2. miR-324-5p contributes to cardiac disease pathophysiology and cardiomyocite death through translational inhibition of Mtfr1, leading to reduced mitochondrial fission, apoptosis, and myocardial infarction.
73. Bromocriptine. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2026 Sep 15. Bromocriptine is usually not used during breastfeeding because it suppresses lactation. The indication of lactation suppression has been withdrawn in the U.S. and discouraged in other countries because it increases the risk of maternal stroke, seizures, cardiovascular disorders, death and possibly psychosis.[1-4] A low dose of 2.5 mg once daily has been used for 3 days to decrease overproduction of milk.[5] The drug was undetectable in milk with this dosage and infants had no adverse reactions, but the safety of this use is not clearly established. Postpartum women may clear bromocriptine more rapidly than others.[6] Case reports and series also exist of mothers treated with bromocriptine for amenorrhea-galactorrhea syndrome or prolactinoma during pregnancy and lactation who successfully breastfed their infants. Bromocriptine has been used to treat persistent galactorrhea following breast augmentation surgery.[7] It has also been used to mitigate hyperprolactinemia and galactorrhea caused by antipsychotic therapy.[8]
Sources: pubmed.ncbi.nlm.nih.gov
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.